Therapeutic Asset Ratings

159 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Humulin R Bipolar Disorder	University Health Network, Toronto	P3	B (60)
Rivaroxaban Central Venous Catheter Thrombosis	University Health Network, Toronto	P3	B (60)
ETOPOSIDE Carcinoma, Pancreatic Ductal	University Health Network, Toronto	P2	B (60)
Teclistamab Refractory Cancer	University Health Network, Toronto	P4	B (59)
Modafinil Modafinil	University Health Network, Toronto	P3	B (59)
Abemaciclib Advanced Cancer	University Health Network, Toronto	P2	B (59)
Durvalumab Head and Neck Squamous Cell Carcinoma	University Health Network, Toronto	P2	B (59)
Talzenna Extensive Stage Lung Small Cell Carcinoma	University Health Network, Toronto	P2	B (59)
Humulin R Major Depressive Disorder	University Health Network, Toronto	P3	B (58)
TRASTUZUMAB Advanced Solid Tumors	University Health Network, Toronto	P3	B (58)
Bendamustine Refractory Malignant Solid Neoplasm	University Health Network, Toronto	P2	B (58)
Cobimetinib Borderline Resectable Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P2	B (58)
Cobimetinib Locally Advanced Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P2	B (58)
Epirubicin Relapsed Cancer	University Health Network, Toronto	P2	B (58)
Olaparib Recurrent Glioma	University Health Network, Toronto	P2	B (57)
Relatlimab Mucosal Melanoma	University Health Network, Toronto	P2	B (57)
CIS-DIAMMINEDICHLOROPLATINUM II PALB2 Gene Mutation	University Health Network, Toronto	P2/3	B (57)
Dpx-Survivac Fallopian Tube Cancer	University Health Network, Toronto	P2	B (56)
Atezolizumab Liver Metastases	University Health Network, Toronto	P2	CCC (55)
Trastuzumab Emtansine Advanced Cancer	University Health Network, Toronto	P2	CCC (55)
Cobimetinib Advanced Cancer	University Health Network, Toronto	P2	CCC (54)
Ponatinib Advanced Cancer	University Health Network, Toronto	P2	CCC (54)
Samuraciclib Pancreas Ductal Adenocarcinoma	University Health Network, Toronto	P1/2	CCC (54)
9-valent human papillomavirus recombinant vaccine Human Papilloma Virus	University Health Network, Toronto	P2	CCC (53)
Abemaciclib Epithelial Tumor	University Health Network, Toronto	P2	CCC (53)

Showing 26 to 50 of 159 assets

PreviousPage 2 of 7Next